证券代码：600568 证券简称：ST 中珠 公告编号：2025-023 号 中珠医疗控股股份有限公司 关于召开 2024 年度业绩说明会的公告 特别提示 中珠医疗控股股份有限公司（以下简称"中珠医疗"或"公司"）已于 2025 年 4 月 19 日发布公司 2024 年度报告，为便于广大投资者更全面深入地了解公司 2024 年度经营 成果、财务状况，公司计划于 2025 年 5 月 15 日（星期四）09:00-10:00 举行 2024 年度 业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2024 年度的经营成果及财务 指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内就投资者普遍 关注的问题进行回答。 二、说明会召开的时间、地点 （二）会议召开地点：上证路演中心 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： http://roadshow.sseinfo.com/） （一）会议召开时间：2025 年 5 月 15 日（星期四）09 ...

证券代码：600568 证券简称：ST 中珠 公告编号：2025-022 号 中珠医疗控股股份有限公司 2025 年第一季度主要经营数据公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上市公司行业信息披露指引第一号——房地产》《上市公司行业信息披露 指引第六号——医药制造》及上海证券交易所《关于做好主板上市公司 2025 年第一季 度报告披露工作的重要提醒》的要求，中珠医疗控股股份有限公司（以下简称"中珠 医疗"或"公司"）现将 2025 年第一季度主要经营数据披露如下： 一、主营业务分析 | 行 业 | 营业收入 | 营业成本 | 毛利率 | 营业收入比 | 营业成本比 | | --- | --- | --- | --- | --- | --- | | | （2025 年 1-3 月） | （2025 年 1-3 月） | | 上年增减（%） | 上年增减（%） | | 医疗器械 | 2,225,707.17 | 1,631,908.30 | 26.68 | -59.06 | -55.10 | | 医疗 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥141,459,196.22, representing an increase of 8.81% compared to ¥130,001,333.73 in the same period last year[3]. - The net profit attributable to shareholders was a loss of ¥17,779,912.53, an improvement of 22.34% from a loss of ¥22,893,608.42 in the previous year[3]. - The basic earnings per share improved to -¥0.0089 from -¥0.0115, reflecting a 22.61% increase[3]. - Net loss for Q1 2025 was ¥17,249,980.56, a decrease in loss compared to ¥20,801,816.79 in Q1 2024, showing an improvement of 17.3%[20]. - The company’s total comprehensive income attributable to the parent company for the current period was CNY -17,698,333.44, an improvement from CNY -22,968,340.17 in the previous period[21]. Cash Flow - The net cash flow from operating activities was ¥24,409,772.73, a significant increase of 206.12% compared to a negative cash flow of ¥23,001,563.66 in the same period last year[3]. - In Q1 2025, the company reported cash inflows from operating activities of CNY 149,667,392.16, an increase of 17.3% compared to CNY 127,578,065.68 in Q1 2024[23]. - The net cash flow from operating activities for Q1 2025 was CNY 24,409,772.73, a significant recovery from a net outflow of CNY 23,001,563.66 in the same period last year[24]. - Cash outflows for purchasing goods and services decreased to CNY 50,127,457.53 in Q1 2025 from CNY 57,293,759.28 in Q1 2024, reflecting a reduction of approximately 12.5%[24]. - Cash outflows for employee compensation in Q1 2025 were CNY 47,391,903.71, down from CNY 62,980,623.05 in Q1 2024, indicating a reduction of approximately 24.8%[24]. - The company’s cash flow from financing activities showed a net outflow of CNY -687,601.20 in Q1 2025, compared to a larger outflow of CNY -110,834,057.69 in Q1 2024[24]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,091,725,890.09, a decrease of 1.36% from ¥2,120,638,022.34 at the end of the previous year[3]. - Total assets decreased to ¥2,091,725,890.09 as of March 31, 2025, down from ¥2,120,638,022.34 at the end of 2024, a decline of 1.4%[16]. - Total liabilities decreased to ¥366,124,147.14 as of March 31, 2025, down from ¥377,867,877.91 at the end of 2024, a reduction of 3.1%[17]. - The company reported a decrease in inventory to ¥273,170,700.44 as of March 31, 2025, from ¥305,700,193.69 at the end of 2024, a decline of 10.6%[15]. Shareholder Information - The company reported a total equity attributable to shareholders of ¥1,731,577,140.25, down 1.01% from ¥1,749,275,473.69[6]. - The company’s total equity attributable to shareholders decreased to ¥1,731,577,140.25 as of March 31, 2025, down from ¥1,749,275,473.69 at the end of 2024, a decline of 1.0%[17]. - The number of ordinary shareholders at the end of the reporting period was 21,462[10]. - The largest shareholder, Shenzhen Landi Technology Development Co., Ltd., holds 19.08% of the shares, amounting to 380,172,862 shares[10]. Operating Costs and Expenses - Total operating costs for Q1 2025 were ¥162,380,842.07, up from ¥151,475,799.64 in Q1 2024, reflecting a year-over-year increase of 7.9%[19]. - Research and development expenses for Q1 2025 were ¥2,519,412.33, slightly up from ¥2,453,616.77 in Q1 2024, indicating a year-over-year increase of 2.7%[20]. - Non-recurring gains and losses amounted to ¥4,959,544.56, with government subsidies contributing ¥1,138,288.99[5][8]. Cash and Equivalents - Cash and cash equivalents increased to ¥424,772,442.85 as of March 31, 2025, up from ¥403,740,148.14 at the end of 2024, representing a growth of 5.1%[15]. - The total cash and cash equivalents at the end of Q1 2025 stood at CNY 336,912,278.95, an increase from CNY 238,998,615.25 at the end of Q1 2024[25].

Financial Performance - The company reported a basic earnings per share of -0.0089 yuan for Q1 2025, an improvement of 22.61% compared to -0.0115 yuan in Q1 2024 [1] - The net profit for Q1 2025 was -0.18 billion yuan, showing a 21.74% increase from -0.23 billion yuan in Q1 2024 [1] - Operating revenue increased by 8.46% to 1.41 billion yuan in Q1 2025, compared to 1.3 billion yuan in Q1 2024 [1] - The return on equity was -1.02% in Q1 2025, slightly worse than -0.94% in Q1 2024 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 83,827.98 million shares, accounting for 50.22% of the circulating shares, with a decrease of 17.45 million shares from the previous period [1] - Shenzhen Landi Technology Development Co., Ltd. remains the largest shareholder with 21,877.26 million shares, representing 13.11% of total share capital [2] - New entrant in the top ten shareholders is Li Songqiang, holding 1,543.61 million shares, which is 0.92% of total share capital [2] Dividend Policy - The company has decided not to distribute dividends or transfer shares in this period [3]

ST中珠（600568）公告，2025年第一季度营收为1.41亿元，同比增长8.81%；净亏损1777.99万元，去年 同期净亏损2289.36万元。 ...

Core Insights - The rise of 5G mobile connectivity has made short videos a crucial communication bridge between brands and consumers, particularly in the liquor industry where traditional marketing methods are losing effectiveness [1] - Niulanshan, a historic Chinese liquor brand, has adapted its strategies over the years, evolving from a regional focus to a national and now international presence, always prioritizing consumer needs [1][16] Brand Development - Niulanshan has emphasized brand culture and storytelling through short videos, integrating its brand philosophy with consumers' daily lives, thus transforming into a cultural symbol [2] - The "Smoke and Fire in the World" series of short films has resonated deeply with audiences, establishing emotional connections between the brand and consumers [3][4] Marketing Strategies - Niulanshan has collaborated with popular variety shows to enhance brand visibility and evoke positive consumer memories associated with taste, linking the brand to local cultures [5] - The brand has built a diverse new media matrix, utilizing platforms like Douyin and WeChat to engage consumers through various content types, enhancing user interaction and brand loyalty [6] Quality and Innovation - Niulanshan maintains traditional brewing techniques while embracing innovation, ensuring high-quality products through strict quality control and premium raw materials [13] - The company is investing in technological advancements and digital transformation to improve production efficiency and enhance consumer shopping experiences [14] Future Outlook - Niulanshan aims to deepen its integration into consumers' lives and maintain its focus on meeting the needs of the masses, which is expected to provide a competitive edge in the market [16]

中珠医疗控股股份有限公司 2024 年年度股东大会会议资料 中珠医疗控股股份有限公司 ZHONGZHU HEALTHCARE HOLDING CO.,LTD 2024 年年度股东大会 会议资料 二〇二五年五月十二日 中国·珠海 中珠医疗控股股份有限公司 2024 年年度股东大会会议资料 目 录 - 2 - 一、2024 年年度股东大会会议议程 二、2024 年年度股东大会会议须知 三、2024 年年度股东大会现场表决办法 四、会议议案 1、审议《公司 2024 年年度报告全文》及摘要； 2、审议《公司 2024 年度财务决算报告》； 3、审议《关于公司 2024 年度利润分配预案的议案》； 4、审议《关于公司 2025 年度对外担保计划的议案》 5、审议《关于计提资产减值准备的议案》； 6、审议《关于公司<2024 年度内部控制评价报告>的议案》； 7、审议《公司 2024 年度董事会工作报告》； 8、审议《公司 2024 年度监事会工作报告》； 9、审议《公司 2024 年度独立董事述职报告》； 10、审议《关于公司非独立董事、独立董事及高级管理人员薪酬的议案》。 中珠医疗控股股份有限公司 2024 年年度 ...

证券代码：600568 证券简称：ST 中珠 公告编号：2025-019 号 中珠医疗控股股份有限公司 关于召开 2024 年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、召开会议的基本情况 至 2025 年 5 月 12 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资 者的投票，应按照《上海证券交易所上市公司自律监管指引第 1 号 — 规 范运作》等有关规定执行。 (七) 涉及公开征集股东投票权 无 二、会议审议事项 本次股东大会审议议案及投票股东类型 | 序号 | | | 议案名称 | | 投票股东 类型 | | --- | --- | --- | --- | --- | --- | | | | | | A | 股股东 | | ...

证券代码：600568 证券简称：ST 中珠 公告编号：2025-014 号 中珠医疗控股股份有限公司 第十届监事会第二次会议决议公告 特别提示 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 1、中珠医疗控股股份有限公司（以下简称"中珠医疗"或"公司"）第十届 监事会第二次会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公 司章程》的规定。 4、本次监事会会议应出席监事 3 人，实际出席监事 3 人。 二、监事会会议审议情况 经与会监事认真审议，通过以下议案： （一）审议通过《公司 2024 年度监事会工作报告》； 表决结果为：同意 3 票，反对 0 票，弃权 0 票。 2024 年度，公司监事会共召开 6 次会议，会议决议内容的签署以及监事权 利的行使符合《公司法》《公司章程》《监事会议事示范规则》的规定。公司监 事会认真履行了监督、检查等职能，对公司法人治理的不断健全和完善起到了积 极的作用。 本议案尚需提交公司 2024 年年度股东大会审议。 （二）审议通过《公司 2024 年年度报告 ...

证券代码：600568 证券简称：ST 中珠 公告编号：2025-013 号 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 1、中珠医疗控股股份有限公司（以下简称"中珠医疗"或"公司"）第十届 董事会第五次会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公 司章程》的规定。 2、本次董事会会议于 2025 年 4 月 7 日以电话、邮件、微信送达方式发出 通知。 3、本次董事会会议于 2025 年 4 月 18 日以现场会议的方式召开。 4、本次董事会会议应出席董事 9 人，实际出席董事 9 人，其中非独立董事 戴绍宏先生授权委托非独立董事麻华先生出席会议并代为表决。公司全体监事 和部分高管列席了本次会议。 二、董事会会议审议情况 经与会董事认真审议，通过以下议案： （一）审议通过《公司 2024 年年度报告全文》及摘要； 中珠医疗控股股份有限公司 第十届董事会第五次会议决议公告 表决结果：同意 9 票，反对 0 票，弃权 0 票。 根据中国证监会《公开发行证券的公司信息披露内容与 ...